Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System).

[1]  Xiao-xi Chen,et al.  Intravoxel incoherent motion diffusion‐weighted imaging in assessing bladder cancer invasiveness and cell proliferation , 2018, Journal of magnetic resonance imaging : JMRI.

[2]  Jin Wang,et al.  The Diagnostic Value of MR Imaging in Differentiating T Staging of Bladder Cancer: A Meta-Analysis. , 2017, Radiology.

[3]  M. Babjuk,et al.  Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review. , 2017, European urology.

[4]  J. Catto,et al.  Long-term Outcomes from Re-resection for High-risk Non-muscle-invasive Bladder Cancer: A Potential to Rationalize Use. , 2017, European urology focus.

[5]  Huyen T. X. Nguyen,et al.  Quantitative Assessment of Heterogeneity in Bladder Tumor MRI Diffusivity: Can Response be Predicted Prior to Neoadjuvant Chemotherapy? , 2017, Bladder cancer.

[6]  S. Shariat,et al.  Novel endoscopic visualization techniques for bladder cancer detection: a review of the contemporary literature , 2017, Current opinion in urology.

[7]  S. Lipsitz,et al.  Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder. , 2017, European urology.

[8]  J. Cho,et al.  Diagnostic performance of MRI for prediction of muscle-invasiveness of bladder cancer: A systematic review and meta-analysis. , 2017, European journal of radiology.

[9]  Steven L. Chang,et al.  Variations in the Costs of Radical Cystectomy for Bladder Cancer in the USA. , 2017, European urology.

[10]  J. Catto,et al.  Radical cystectomy (bladder removal) against intravesical BCG immunotherapy for high-risk non-muscle invasive bladder cancer (BRAVO): a protocol for a randomised controlled feasibility study , 2017, BMJ Open.

[11]  A. Niemierko,et al.  Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. , 2017, European urology.

[12]  M. Amin,et al.  Challenges in Pathologic Staging of Bladder Cancer: Proposals for Fresh Approaches of Assessing Pathologic Stage in Light of Recent Studies and Observations Pertaining to Bladder Histoanatomic Variances. , 2017, Advances in anatomic pathology.

[13]  Maximilian Burger,et al.  EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. , 2017, European urology.

[14]  E. Compérat,et al.  Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. , 2017, European urology.

[15]  Carlo Catalano,et al.  An evaluation of morphological and functional multi-parametric MRI sequences in classifying non-muscle and muscle invasive bladder cancer , 2017, European Radiology.

[16]  R. Huddart,et al.  Use of diffusion weighted-MRI (DW-MRI) as a prognostic biomarker of survival and time to cystectomy in muscle invasive bladder cancer (MIBC) following organ conserving treatment , 2017 .

[17]  Katarzyna J Macura,et al.  Reply to Erik Rud and Eduard Baco's Letter to the Editor re: Re: Jeffrey C. Weinreb, Jelle O. Barentsz, Peter L. Choyke, et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. Eur Urol 2016;69:16-40. , 2016, European urology.

[18]  Stuart A. Taylor,et al.  Imaging biomarker roadmap for cancer studies , 2016, Nature Reviews Clinical Oncology.

[19]  Yan Guo,et al.  Comparison of Early Submucosal Enhancement and Tumor Stalk in Staging Bladder Urothelial Carcinoma. , 2016, AJR. American journal of roentgenology.

[20]  Holger Moch,et al.  The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. , 2016, European urology.

[21]  Valeria Panebianco,et al.  Improving Staging in Bladder Cancer: The Increasing Role of Multiparametric Magnetic Resonance Imaging. , 2016, European urology focus.

[22]  H. Rashid,et al.  Bladder Neck Urothelial Carcinoma , 2015, International journal of surgical pathology.

[23]  A. Vickers,et al.  Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature. , 2015, European urology.

[24]  Xiangyu Yang,et al.  Prediction of chemotherapeutic response in bladder cancer using K‐means clustering of dynamic contrast‐enhanced (DCE)‐MRI pharmacokinetic parameters , 2015, Journal of magnetic resonance imaging : JMRI.

[25]  R. Eeles,et al.  Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder , 2015, British Journal of Cancer.

[26]  R. Mak,et al.  Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Dirk Zaak,et al.  Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations. , 2014, European urology.

[28]  Zhongqiu Wang,et al.  Contrast-enhanced dynamic and diffusion-weighted MR imaging at 3.0T to assess aggressiveness of bladder cancer. , 2014, European journal of radiology.

[29]  G. Lyratzopoulos,et al.  Inequalities in reported cancer patient experience by socio-demographic characteristic and cancer site: evidence from respondents to the English Cancer Patient Experience Survey , 2014, European journal of cancer care.

[30]  S. Shariat,et al.  Quantitative Apparent Diffusion Coefficient Measurements Obtained by 3-Tesla MRI Are Correlated with Biomarkers of Bladder Cancer Proliferative Activity , 2014, PloS one.

[31]  Y. Lotan,et al.  The economics of bladder cancer: costs and considerations of caring for this disease. , 2014, European urology.

[32]  Sam S. Chang,et al.  Incidence and predictors of understaging in patients with clinical T1 urothelial carcinoma undergoing radical cystectomy , 2014, BJU international.

[33]  J. Witjes,et al.  EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. , 2014, European urology.

[34]  H. Mostafid,et al.  Falling bladder cancer incidence from 1990 to 2009 is not producing universal mortality improvements , 2014 .

[35]  Yan Guo,et al.  Diffusion-weighted MRI in bladder carcinoma: the differentiation between tumor recurrence and benign changes after resection , 2014, Abdominal Imaging.

[36]  Kazutaka Saito,et al.  Apparent diffusion coefficient value reflects invasive and proliferative potential of bladder cancer , 2014, Journal of magnetic resonance imaging : JMRI.

[37]  Lucy E Kershaw,et al.  Dynamic contrast-enhanced MRI in patients with muscle-invasive transitional cell carcinoma of the bladder can distinguish between residual tumour and post-chemotherapy effect. , 2013, European journal of radiology.

[38]  Yuta Shibamoto,et al.  MR imaging of urinary bladder cancer for T‐staging: A review and a pictorial essay of diffusion‐weighted imaging , 2013, Journal of magnetic resonance imaging : JMRI.

[39]  M. Babjuk,et al.  EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. , 2013, European urology.

[40]  J. Catto,et al.  Competing mortality in patients diagnosed with bladder cancer: evidence of undertreatment in the elderly and female patients , 2013, British Journal of Cancer.

[41]  M. Abbod,et al.  Disease specific mortality in patients with low risk bladder cancer and the impact of cystoscopic surveillance. , 2013, The Journal of urology.

[42]  Tarek El-Diasty,et al.  Diffusion‐weighted magnetic resonance imaging in follow‐up of superficial urinary bladder carcinoma after transurethral resection: initial experience , 2012, BJU international.

[43]  A. Graser,et al.  Staging of muscle-invasive bladder cancer: can computerized tomography help us to decide on local treatment? , 2012, World Journal of Urology.

[44]  R. Wahlqvist,et al.  Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. , 2012, European urology.

[45]  Kazutaka Saito,et al.  Clinical Investigation : Genitourinary Cancer Role of Diffusion-Weighted Magnetic Resonance Imaging in Predicting Sensitivity to Chemoradiotherapy in Muscle-Invasive Bladder Cancer , 2012 .

[46]  Emma Hall,et al.  Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. , 2012, The New England journal of medicine.

[47]  A. Niemierko,et al.  Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. , 2012, European urology.

[48]  J. Witjes,et al.  Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. , 2011, European urology.

[49]  M. Parmar,et al.  International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  G J M Parker,et al.  Comparison of dynamic contrast‐enhanced MRI and dynamic contrast‐enhanced CT biomarkers in bladder cancer , 2011, Magnetic resonance in medicine.

[51]  K. Kihara,et al.  Initial experience of diffusion-weighted magnetic resonance imaging to assess therapeutic response to induction chemoradiotherapy against muscle-invasive bladder cancer. , 2010, Urology.

[52]  A. Finelli,et al.  Cost‐effectiveness analysis of immediate radical cystectomy versus intravesical Bacillus Calmette‐Guerin therapy for high‐risk, high‐grade (T1G3) bladder cancer , 2009, Cancer.

[53]  M. Okada,et al.  [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)]. , 2009, Gan to kagaku ryoho. Cancer & chemotherapy.

[54]  H. Hricak,et al.  Imaging appearance of granulomatous disease after intravesical Bacille Calmette-Guerin (BCG) treatment of bladder carcinoma. , 2009, AJR. American journal of roentgenology.

[55]  Yuta Shibamoto,et al.  Urinary bladder cancer: diffusion-weighted MR imaging--accuracy for diagnosing T stage and estimating histologic grade. , 2009, Radiology.

[56]  J. Gore,et al.  Mortality increases when radical cystectomy is delayed more than 12 weeks , 2009, Cancer.

[57]  P. Schellhammer,et al.  Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. , 2007, The Journal of urology.

[58]  R. Swindell,et al.  The value of hyoscine butylbromide in pelvic MRI. , 2007, Clinical radiology.

[59]  J. Wong-You-Cheong,et al.  From the archives of the AFIP: Inflammatory and nonneoplastic bladder masses: radiologic-pathologic correlation. , 2006, Radiographics : a review publication of the Radiological Society of North America, Inc.

[60]  J O Barentsz,et al.  Evaluation of chemotherapy with magnetic resonance imaging in patients with regionally metastatic or unresectable bladder cancer. , 2006, European urology.

[61]  J Alfred Witjes,et al.  Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. , 2006, European urology.

[62]  C. Vale.  Neoadjuvant Chemotherapy in Invasive Bladder Cancer: Update of a Systematic Review and Meta-Analysis of Individual Patient Data: Advanced Bladder Cancer (ABC) Meta-analysis Collaboration , 2005 .

[63]  V. Ficarra,et al.  Correlation between clinical and pathological staging in a series of radical cystectomies for bladder carcinoma , 2005, BJU international.

[64]  C. Siegel.  Bladder cancer: analysis of multi-detector row helical CT enhancement pattern and accuracy in tumor detection and perivesical staging. , 2005, The Journal of urology.

[65]  Jeong Kon Kim,et al.  Bladder cancer: analysis of multi-detector row helical CT enhancement pattern and accuracy in tumor detection and perivesical staging. , 2004, Radiology.

[66]  Nicholas J Vogelzang,et al.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. , 2003, The New England journal of medicine.

[67]  C. Sternberg,et al.  Can patient selection for bladder preservation be based on response to chemotherapy? , 2003, Cancer.

[68]  Marcus Settles,et al.  Reliability of MR imaging-based virtual cystoscopy in the diagnosis of cancer of the urinary bladder. , 2002, AJR. American journal of roentgenology.

[69]  Laurence Collette,et al.  Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. , 2002, European urology.

[70]  S. Groshen,et al.  Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  J. Kawamura,et al.  A new staging criterion for bladder carcinoma using gadolinium‐enhanced magnetic resonance imaging with an endorectal surface coil: a comparison with ultrasonography , 2000, BJU international.

[72]  R. Macchia,et al.  Long-term consequences from bladder perforation and/or violation in the presence of transitional cell carcinoma: results of a small series and a review of the literature. , 1999, The Journal of urology.

[73]  J. Witjes,et al.  Evaluation of chemotherapy in advanced urinary bladder cancer with fast dynamic contrast-enhanced MR imaging. , 1998, Radiology.

[74]  N Karssemeijer,et al.  Staging urinary bladder cancer after transurethral biopsy: value of fast dynamic contrast-enhanced MR imaging. , 1996, Radiology.

[75]  P. Carroll,et al.  Bladder tumor staging: comparison of contrast-enhanced CT, T1- and T2-weighted MR imaging, dynamic gadolinium-enhanced imaging, and late gadolinium-enhanced imaging. , 1994, Radiology.

[76]  J. Barentsz,et al.  The role of MR imaging in carcinoma of the urinary bladder. , 1993, AJR. American journal of roentgenology.

[77]  S. Ishiguro,et al.  Bladder wall morphology: in vitro MR imaging-histopathologic correlation. , 1993, Radiology.

[78]  K. Kuriyama,et al.  Bladder tumors: staging with gadolinium-enhanced oblique MR imaging. , 1993, Radiology.

[79]  N. Vogelzang,et al.  The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer--Genitourinary Group. , 1992, The Journal of urology.

[80]  I. Isherwood,et al.  Accuracy in staging carcinoma of the bladder by magnetic resonance imaging. , 1990, Clinical radiology.

[81]  F. Saad,et al.  Curative Treatment for Muscle Invasive Bladder Cancer in Elderly Patients: A Systematic Review. , 2018, European urology.

[82]  Jacques Ferlay,et al.  Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. , 2017, European urology.

[83]  D. Margolis,et al.  PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. , 2016, European urology.

[84]  O. Patschan,et al.  Transurethral bladder tumor resection can cause seeding of cancer cells into the bloodstream. , 2015, The Journal of urology.

[85]  L. Kiemeney,et al.  Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients. , 2015, European urology.

[86]  R. Huddart,et al.  PO-0734: Assessing response to radiotherapy with diffusion weighted MRI (DW-MRI) in muscle invasive bladder cancer (MIBC) , 2014 .

[87]  M. Babjuk,et al.  ICUD-EAU International Consultation on Bladder Cancer 2012: Non-muscle-invasive urothelial carcinoma of the bladder. , 2013, European urology.

[88]  J. Catto,et al.  Comparative outcomes of primary, recurrent, and progressive high-risk non-muscle-invasive bladder cancer. , 2013, European urology.

[89]  J. Gschwend,et al.  An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. , 2010, European urology.

[90]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.